information and how to take advantage of this effort. The majority of them believe that one possible benefit of this information is to use it to understand the genetic basis of the most common familial traits, evolutionary processes, and complex and common diseases such as hypertension, diabetes, obesity, and psychiatric disorders. These common diseases are likely to be caused by multiple genes and multiple nongenetic factors (environmental factors), each contributing a modest effect. Their cumulative effect results in the condition or trait. The traditional methods of identifying disease-related genes are not readily applicable to the detection of genes responsible for these multifactorial diseases. The availability of the entire genome sequence, therefore, may speed up the gene-hunting efforts in the near future, but what approaches are to be taken to accomplish this task and what are their limitations?
Introduction
It is now clear that mapping the entire human genome sequence is a reality and will be completed by the year 2003. Many investigators now have to decide what to do with this or DNA and pre-mRNA conformation, and play a direct or indirect role in phenotypic expression (Krawezak et al. 1992; Lohrer and Tangen 2000; Pitarque et al. 2001; Spicker et al. 2001; LeVan et al. 2001) . Because some SNPs are functional, comparative studies on identical twins, fraternal twins, and siblings suggest that genetic variation is one of the factors associated with susceptibility to many common diseases (Table 1) as well as every human trait such as tallness, curly hair, and individuality (Martin et al. 1997) . Diversity in the population is also associated with these variations. Therefore, it may be possible to understand why some individuals are susceptible to common disorders by using the human genome sequence and the variations between individuals. However, there are limitations, and practical and ethical issues must be considered before undertaking such analyses (Chanock 2001) .
Mapping and characterization of SNPs
Because most sequence variants are SNPs, a massive effort has been undertaken by several private and public organizations, such as Celera Genomics, Incyte Genomics, the Wellcome Trust Sanger Institute in the United Kingdom, and Washington University in the United States, to generate a high-density SNP map of the genome Irizarry et al. 2000; Altshuler et al. 2000; Mullikin et al. 2000 ; also see the International SNP Map Working Group 2001 and http://www.ncbi.nlm.nih.gov/SNP/). As a result of this worldwide intensive effort, more than 2.8 million SNPs have been identified and a high-density map has been constructed in some cases (Iida et al. 2001a-d; Iwasaki et al. 2001; Saito et al. 2001; Osier et al. 2001) . Although several mapping methods (Table 2) , such as single-strand conformational polymorphism (Orita et al. 1989) , denaturing gradient gel electrophoresis (DGGE), enzymatic mutation detection (Youil et al. 1995) , microarray or variant detector arrays (Wang et al. 1998; Marshall and Hodgson 1998; Ramsay 1998; Dong et al. 2001; Qi et al. 2001; Yoshino et al. 2001) , and heteroduplex analysis (Lichten and Fox 1983) are available, so far none of them has supplanted DNA sequencing as the method of choice. SNP mapping requires a tremendous amount of time and resources (hundreds and thousands of individuals must be studied to eliminate false-positive and false-negative results). Additionally, many of the methods detect only about 80% of mutations. In some methods, mutations in GC-rich regions may not be detected (e.g., DGGE), and other methods involve expensive instruments and kits or toxic chemicals (Table 2) . Therefore, new, faster methods must be developed and old methods refined so that, at least, cost is not a key consideration. In this respect, recently developed high-throughput SNP genotyping (Jenkins and Gibson 2002; McClay et al. 2002) and molecular beacon methods (Mhlanga and Malmberg 2001) are highly valuable. According to some estimates, 50% of mutations are likely to be in a noncoding sequence, 25% lead to amino acid substitution, and 25% are silent (Cargill et al. 1999; Halushka et al. 1999 ). However, it should be noted that the above estimates are only for cSNPs (SNPs found in protein-coding regions) and SNPs in untranslated regions and depend on sample size because they have different allele frequency distributions. 
SNPs in gene discovery
Once the map of these SNPs is confirmed, they can be used for evolutionary biology studies, gene discovery and mapping, prediction of drug and environmental response, diagnostic tests, heterogeneity testing, and association studies (Gray et al. 2000; Schork et al. 2000) . For the purpose of gene discovery, SNPs are considered to be the most predominant segregating form of variation at the molecular level because of their frequent occurrence throughout the genome, and they can be useful in association studies. However, they are less informative, in the sense that humans have relatively low nucleotide diversity compared with Drosophila and maize, than another type of marker called a microsatellite. Microsatellites are simple sequence repeats, the most common classes being dinucleotide, trinucleotide, and tetranucleotide, and they occur at a rate of 1 in every 10 kb in a wide range of eukaryotic genomes. Human microsatellites are used for linkage studies and they average at least ten alleles with heterozygosity per locus over 80% (very high). Although they have a much higher mutation rate than the standard sequence, they are not densely distributed. Linkage mapping focuses on the small number of meiotic events within a family and association between marker alleles and traits. It does not require a very dense map of markers at the initial stage. On the other hand, linkage disequilibrium mapping explores family associations and requires a dense map of markers. In association studies, the marker is prevalent in patients versus those without the disease and this is considered evidence of association between the disease and the marker (SNP). Although there are many limitations (described following), association studies are perhaps the best for mapping of polygenic complex disease loci. However, this type of study requires a large number of patients and an adequate control group to achieve over 80% power to detect a locus. Once a significant site is identified, one can use either a pedigreebased transmission disequilibrium test (TDT), which measures the transmission of alleles from a heterozygous parent to the affected offspring (an unequal transmission of SNP alleles to affected and unaffected siblings), or a case-control population sampling, which measures the association between SNPs and the disease in a large population (Keavney et al. 2000; Spielman et al. 1992) . TDT detects both linkage and association, and SNPs are usually used. These methods are based on the assumption that SNP variants account for population susceptibility to certain disorders; however, it is unknown how many SNPs are needed. These methods have several limitations, such as difficulties associated with population structure, different levels of linkage disequilibrium in loci, allelic and nonallelic heterogeneity of phenotypes, and epistatic interaction of alleles, all of which have been previously discussed by others (Schork et al. 2000; Chakravarti 1999; Weiss and Terwilliger 2000) . An allele frequency database for human polymorphic sites for multiple populations (Osier et al. 2001; Hirakawa et al. 2002) can be found on the Kidd lab home page (http://info.med.yale.edu/genetics/kkidd/). Additionally, a recently proposed haplotype (a distinct combination of single nucleotide types on a single chromosome at a locus) map (Fig. 1B) of the genome may speed up or simplify the hunt for the association between DNA variations and complex diseases (Helmuth 2001) . This is because haplotype diversity, which is greater than SNP diversity, may be generated by new SNP alleles that can arise because of mutation at different loci, and hence can be studied by both linkage and association methods. In haplotype association studies, multitype genotypes are reduced to haplotypes and this has proved to be a more efficient mapping technique than that of SNP analysis.
SNPs in pharmacology
Another potential application of SNPs is the development of individualized medicine. Inherited genetic differences between individuals appear to determine each patient's response to medicine. For instance, some patients show response to the prescribed drug without any serious side effects, whereas others do not respond and experience adverse reactions. In fact, it is estimated that properly prescribed medications cause 2 million Americans to get sick and result in 100 000 deaths each year because of adverse (Pirmohamed and Park 2001; Bader 2001; Wolf et al. 2000; Lazarou et al. 1998 ). Antitumor agent 6-mercaptopurine, for example, has been used for children with leukemia. Those children who do not have its metabolizing enzyme -thiopurine methyltransferase -show a severe hematopoietic toxicity, whereas children with the more active enzyme require higher doses of the drug. Similar anti-drug reactions were also observed in asthma and other conditions (Drazen et al. 1999; Roses 2000) . The most important of the several hundred thousand SNPs in the human genome for this purpose are SNPs in drug-metabolizing enzymes, particularly in the coding and the promoter regions, because changes there may have functional significance (Risch 2000) . The SNP method can also be applied to crop (corn and soybean) genetics (Rafalski 2002) . Haplotype analysis is possible for crop genetics because of the availability of many genes and expressed sequence tags, as well as their intraspecific nucleotide diversity.
SNPs and evolution
SNPs can be used to study DNA sequence variation among species. Because such variations are present at all levels of evolution, including branching points of speciation, they may provide an understanding of how the modern genome evolved. Most SNPs are not in protein-coding regions but are elsewhere in the genome; therefore, their distribution is not under selective pressure. Variations in the proteincoding region that affect the phenotype might be subject to natural selection, but if these variations were retained in the gene over time, then they must have some benefit for the individual for successful reproduction. The variants that are selected for retention by natural selection may represent an important step in evolution. Thus, by calculating a ratio between variants in noncoding and coding regions of a series of protein families found in different species, it may be possible to trace the branching point of an evolutionary tree. At this branch point, the variant must have become advantageous for the species and hence fixed in the gene pool (Osier et al. 2001; Stephens et al. 2001; Liberles 2001) . While this gene pool has been continuously expanding during evolution, it might have resulted in the modern human genome. It is very well known from several studies that humans are similar to chimpanzees at the genomic level. However, there are differences between humans and chimpanzees. For instance, malaria; rheumatoid arthritis; and breast, colon, and lung cancers are extremely rare in chimpanzees but common in humans. In this regard, SNPs may provide important health clues.
Conclusion
There is no doubt that the identification of genes underlying polygenic and complex diseases such as psychiatric disorders, diabetes, hypertension, and asthma is of paramount interest for clinicians, geneticists, patients, and the public. However, it is not clear at present how genetic variation alone determines the susceptibility of an individual to some diseases or to adverse drug interactions. This is because most common traits and phenotypes are the result of longterm interaction between genetic and nongenetic environmental factors. Factors such as lifestyle and diet may contribute to disease susceptibility by altering gene expression. Frequency of polymorphism may also vary among different populations (Wakeley et al. 2000; Nielsen 2000; Nielsen and Slatkin 2000) . Therefore, even after complete sequencing and identification of SNPs in an individual's DNA, it is not simple to associate these variations to disease without knowing the functional significance of the identified SNPs. Additionally, researchers are struggling to understand disease heterogeneity even in monogenic disorders. In multigenic disorders, the contribution of susceptible individual genes to the disorder is very weak. Therefore, genotype alone is not sufficient to predict or of susceptibility to disease (Martin et al. 1997) nor is phenotype variation alone necessarily linked to DNA sequence variation (Lander and Schork 1994; Weeks and Lathrop 1995) . On the other hand, finding out how SNPs affect an individual's health and transforming this knowledge into the development of new medicine, which requires the correlation of SNPs with specific diseases, will revolutionize the treatment of most common killer diseases. This is because such an understanding of the relationship between SNPs and the disease will allow clinicians to determine whether an individual will respond to a medicine or experience serious side effects. Drug companies will be able to design different drugs for each patient with similar clinical symptoms or disease phenotypes. In future, this knowledge may give clinicians more insight into the disease and change the definition of some disorders.
